Iterum Therapeutics posts Q4 net loss $12.4M; NDA resubmission planned early Q2 2024

Iterum Therapeutics plc

Net loss of $12.4M for Q4 2023; full year 2023 net loss $38.4M; non-GAAP net loss $10.7M (Q4) and $43.8M (FY).
Cash, equivalents & short-term investments $23.9M at Dec 31; raised $7.1M post-period via ATM, extending cash runway into 2025.
NDA resubmission for oral sulopenem in uUTIs on track for early Q2 2024; FDA action expected early Q4 2024 under 6-month review.
Engaged financial advisor to explore strategic alternatives including a sale or license of sulopenem rights.
R&D expenses rose to $9.7M (Q4) and $40.0M (FY) driven by the REASSURE trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Iterum Therapeutics plc reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 28, 2024, Iterum Therapeutics plc issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023.

View on SEC.gov

325 earnings releases filed in the last 30 days. Browse all earnings releases →

Iterum Therapeutics plc filing history →

Source: SEC EDGAR

accession 0000950170-24-038414

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.